Skip to main content Accessibility help

Study of progesterone for the prevention of preterm birth in twins (STOPPIT): Findings from a trial-based cost-effectiveness analysis

  • Oya Eddama (a1), Stavros Petrou (a1), Dean Regier (a1), John Norrie (a2), Graeme MacLennan (a3), Fiona Mackenzie (a4) and Jane E. Norman (a5)...


Objectives: Preterm birth contributes to a range of healthcare problems amongst infants surmounting to sizeable healthcare costs. Twin pregnancies are at particular risk of preterm birth. The objective of this study was to assess the cost-effectiveness of vaginal progesterone gel for the prevention of preterm birth in twin pregnancies.

Methods: An economic evaluation was conducted alongside a randomized placebo controlled trial (the STOPPIT trial) of vaginal progesterone gel for the prevention of preterm birth in twin pregnancies. Five hundred women were recruited from nine maternity hospitals in the United Kingdom. The outcomes of the economic evaluation were presented in terms of net benefit statistics, cost-effectiveness acceptability curves, generated using the nonparametric bootstrap method, and the expected value of perfect information.

Results: Mean health service costs between the period of randomization and discharge for mother and infant were £28,031 in the progesterone group and £25,972 in the placebo group, generating a mean nonsignificant cost difference of £2,059 (bootstrap mean cost difference £2,334; 95 percent confidence interval: −£5,023, £9,142; p = .33). The probability of progesterone being cost-effective was 20 percent at a willingness to pay threshold of £30,000 per preterm birth prevented. There is little economic justification for conducting further research into the use of vaginal progesterone gel in twin pregnancies for the prevention of preterm birth.

Conclusions: Further studies of preventive interventions for preterm birth more generally are required given the scale of the clinical and economic burden of this condition. These studies should be sufficiently powered for economic endpoints and extend beyond hospital discharge.



Hide All
1. Barber, JA, Thompson, SG. Analysis of cost data in randomized trials: An application of the non-parametric bootstrap. Stat Med. 2000;19:32193236.
2. Berghella, V, Odibo, AO, To, MS, et al. Cerclage for short cervix on ultrasonography: Meta-analysis of trials using individual patient-level data. Obstet Gynecol. 2005;106:181189.
3. Black, WC. The cost-effectiveness plane: A graphical representation of cost-effectiveness. Med Decis Making. 1990;10:212214.
4. Blondel, B, Kogan, MD, Alexander, GR, et al. The impact of the increasing number of multiple births on the rates of preterm birth and low birthweight: An international study. Am J Pubic Health. 2002;92:13231330.
5. Caritis, SN, Rouse, DJ, Peaceman, AM, et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: A randomized controlled trial. Obstet Gynecol. 2009;113 (pt 1):285292.
6. Curtis, LA, ed. Unit costs of health and social care 2007. Canterbury, United Kingdom: Personal Social Services Research Unit, University of Kent; 2007.
7. Department of Health. National schedule for reference costs. London: DoH; 2008.
8. Dodd, JM, Flenady, VJ, Cincotta, R, Crowther, CA. Progesterone for the prevention of preterm birth: A systematic review. Obstet Gynecol. 2007;112:127134.
9. Drummond, MF, O'Brien, B, Stoddart, GL, Torrance, G. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1997.
10. Fenwick, E, Claxton, K, Sculpher, M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779787.
11. Hintz, SR, Kendrick, DE, Vohr, BR, et al. National Institute of Child Health and Human Development Neonatal Research Network. Changes in neurodevelopmental outcomes at 18 to 22 months’ corrected age among infants of less than 25 weeks’ gestational age born in 1993–1999. Pediatrics. 2005;115:16451651.
12. Lim, AC, Bloemenkamp, KWM, Boer, K, et al. Study protocol: Progesterone for the prevention of preterm birth in women with multiple pregnancies: The AMPHIA trial. BMC Pregnancy Childbirth. 2007;7:7.
13. Mugford, M, Hutton, G, Fox-Rushby, J. Methods for economic evaluation alongside a multicentre trial in developing countries: A case study form the WHO Antenatal Care Randomised Controlled Trial. Paediatr Perinat Epidemiol. 1998;12:7597.
14. National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal. NICE: London; 2004.
15. Norman, JN, Mackenzie, F, Owen, P, et al. A randomised, double blind placebo controlled STudy of Progesterone for the Prevention of Preterm Birth In Twins (STOPPIT), and a meta-analysis of the use of progesterone for prevention of preterm birth in twin pregnancy. Lancet. 2009;373:20342040.
16. Office for National Statistics. Birth statistics. (accessed December 2009).
17. Papiernik, E, Keith, L, Oleszczuk, JJ, Cervantes, A. What interventions are useful in reducing the rate of preterm delivery in twins? Clin Obstet Gynecol. 1998;41:1323.
18. Petrou, S, Mehta, Z, Hockley, C, et al. The impact of preterm birth on hospital inpatient admissions and costs during the first five years of life. Pediatrics. 2003;112:12901297.
19. Petrou, S. Economic consequences of preterm birth and low birthweight. BJOG. 2003;110 (Suppl 20):1723.
20. Raikou, M, Briggs, A, Gray, A, McGuire, A. Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. Health Econ. 2000;9:191198.
21. Repka, MX. Ophthalmological problems of the premature infant. Ment Retard Dev Disabil Res Rev. 2000;8:249257.
22. Rouse, DJ, Caritis, SN, Peaceman, AM, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Eng J Med. 2007;357:454461
23. Stinnett, AA, Mullahy, J. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18:S68S80.
24. van Baar, AL, van Wassenaer, AG, Briet, JM, et al. Very preterm birth is associated with disabilities in multiple developmental domains. J Pediatr Psychol. 2005;30:247255


Study of progesterone for the prevention of preterm birth in twins (STOPPIT): Findings from a trial-based cost-effectiveness analysis

  • Oya Eddama (a1), Stavros Petrou (a1), Dean Regier (a1), John Norrie (a2), Graeme MacLennan (a3), Fiona Mackenzie (a4) and Jane E. Norman (a5)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed